Cullinan Oncology Llc Stock Alpha and Beta Analysis
| CGEM Stock | USD 12.54 0.32 2.62% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cullinan Oncology LLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cullinan Oncology over a specified time horizon. Remember, high Cullinan Oncology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cullinan Oncology's market risk premium analysis include:
Beta 2.08 | Alpha (0.73) | Risk 3.65 | Sharpe Ratio (0.16) | Expected Return (0.57) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cullinan |
Cullinan Oncology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cullinan Oncology market risk premium is the additional return an investor will receive from holding Cullinan Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cullinan Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cullinan Oncology's performance over market.| α | -0.73 | β | 2.08 |
Cullinan Oncology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cullinan Oncology's Buy-and-hold return. Our buy-and-hold chart shows how Cullinan Oncology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cullinan Oncology Market Price Analysis
Market price analysis indicators help investors to evaluate how Cullinan Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cullinan Oncology shares will generate the highest return on investment. By understating and applying Cullinan Oncology stock market price indicators, traders can identify Cullinan Oncology position entry and exit signals to maximize returns.
Cullinan Oncology Return and Market Media
The median price of Cullinan Oncology for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 16.49 with a coefficient of variation of 9.29. The daily time series for the period is distributed with a sample standard deviation of 1.54, arithmetic mean of 16.58, and mean deviation of 1.15. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 176 shares by Jennifer Michaelson of Cullinan Oncology at 13.11 subject to Rule 16b-3 | 08/30/2024 |
2 | Disposition of 319 shares by Jeffrey Trigilio of Cullinan Oncology at 13.11 subject to Rule 16b-3 | 09/04/2024 |
3 | Disposition of 8000 shares by Jennifer Michaelson of Cullinan Oncology at 18.09 subject to Rule 16b-3 | 09/05/2024 |
4 | Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus | 09/17/2024 |
5 | Cullinan Therapeutics Files Investigational New Drug Application with FDA for CLN-978 for Treatment of Systemic Lupus Erythematosus - Lupus Foundation of Americ... | 09/23/2024 |
6 | Renaissance Technologies LLC Has 7.36 Million Position in Cullinan Therapeutics, Inc. - MarketBeat | 09/26/2024 |
7 | Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to S... | 10/16/2024 |
8 | Cullinan Therapeutics Research Coverage Started at UBS Group | 10/24/2024 |
9 | Vanguard Group Incs Strategic Acquisition in Cullinan Therapeutics Inc | 11/05/2024 |
10 | Cullinan Therapeutics Q3 Earnings Snapshot | 11/07/2024 |
11 | Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | 11/14/2024 |
12 | Cullinan Therapeutics Is In A Good Position To Deliver On Growth Plans | 11/20/2024 |
About Cullinan Oncology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cullinan or other stocks. Alpha measures the amount that position in Cullinan Oncology LLC has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2023 | 2024 (projected) | Interest Debt Per Share | 0.003941 | 0.0347 | 0.0364 | Revenue Per Share | 0.43 | 0.38 | 0.34 |
Cullinan Oncology Upcoming Company Events
As portrayed in its financial statements, the presentation of Cullinan Oncology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cullinan Oncology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cullinan Oncology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cullinan Oncology. Please utilize our Beneish M Score to check the likelihood of Cullinan Oncology's management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cullinan Oncology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Cullinan Oncology Backtesting, Cullinan Oncology Valuation, Cullinan Oncology Correlation, Cullinan Oncology Hype Analysis, Cullinan Oncology Volatility, Cullinan Oncology History and analyze Cullinan Oncology Performance. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Cullinan Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.